Dressler syndrome

Article written and reviewed by Dr Luca Moretti

Dressler syndrome is a delayed inflammatory pleuropericarditis that occurs after myocardial infarction and belongs to the spectrum of post-cardiac injury syndromes. The latency period, generally lasting weeks, reflects an immune and autoinflammatory mechanism triggered by injury rather than simple local propagation of necrosis. The post-injury response may involve the pericardium, pleurae, and, less often, lung parenchyma. The condition is now rare because of early reperfusion.
The condition must not be confused with early post-infarction pericarditis, which usually emerges one to three days after an extensive infarction through contiguity with the epicardial surface. Dressler syndrome instead requires a latency period and tends to present with a more evident systemic syndrome, including fever, malaise, and pleural involvement; clinical timing is therefore part of the diagnosis. Overlap exists and requires an integrated assessment.

Chest pain after a recent coronary syndrome must not be labeled Dressler syndrome before reocclusion, stent thrombosis, pulmonary embolism, heart failure, infection, and mechanical complications have been excluded. Diagnosis is contextual and requires evidence of inflammation, not merely a temporal association; the diagnosis of exclusion protects against potentially serious therapeutic delays. ECG, echocardiography, and biomarker trends form the initial core assessment.
Treatment of symptomatic disease uses high-dose aspirin, which is preferred after infarction, and colchicine, with gastroprotection and individual adjustments. Glucocorticoids are reserved for contraindications or refractory disease because they may promote dependence and recurrence, while anti-IL-1 agents belong to treatment pathways for selected refractory recurrent pericarditis. The anti-inflammatory strategy must account for ischemic heart disease and bleeding risk. An asymptomatic effusion does not automatically require medication.

Its contemporary rarity makes randomized trials dedicated exclusively to Dressler syndrome unlikely: many recommendations are extrapolated from acute and recurrent pericarditis and other post-cardiac injury syndromes; this indirect evidence must be acknowledged, especially for advanced drugs and duration; the quality of evidence differs between conventional therapy and the post-infarction subgroup. A general recommendation does not automatically demonstrate the same magnitude of benefit in this rare syndrome.
This monograph therefore uses proportionate language: it distinguishes what guidelines recommend for pericarditis from what has been studied directly after infarction; this distinction prevents consensus and extrapolation from being transformed into nonexistent therapeutic certainties. Contextualized evidence nevertheless permits sound clinical decisions. The patient should understand the expected benefits, uncertainties, and possible adverse effects of the alternatives.

Etiology, risk factors, pathogenesis, and pathophysiology

Myocardial injury releases normally unexposed intracellular antigens and molecular danger signals. The innate immune system activates cytokines and inflammatory cells, while an adaptive response may develop during the latency period and recognize cardiac components. Antigen exposure provides a plausible model for delayed onset. Individual autoantibodies, however, are neither diagnostic tests nor a complete explanation for every case.
Blood in the pericardial space may intensify the response by providing antigens, fibrin, and degradation products. Small hemopericardia after necrosis or procedures may be clinically silent initially and subsequently contribute to the syndrome; pericardial blood is a recognized stimulus in post-cardiac injury syndromes. Its presence is neither necessary nor sufficient and always requires exclusion of rupture.

The reduction in the syndrome during the PCI era supports the role of injury size. Rapid reperfusion limits necrosis, antigen exposure, and inflammation, whereas late presentation and a large infarction increase the substrate; infarct size is a probable determinant. Historical estimates cannot be transferred directly to contemporary cohorts.
The response may involve both serosal membranes because the pericardium and pleura share the ability to produce inflammatory exudate. Pleural involvement explains respiratory pain, a friction rub, and effusions, whereas congestion from heart failure alone produces a transudate with a different significance; pleuropericarditis characterizes many complete presentations. The nature of the fluid is investigated only when drainage is clinically indicated.

Interleukin-1 occupies a central position in autoinflammatory recurrent pericarditis and explains the efficacy of targeted blockade in selected phenotypes. However, there are no large clinical studies specific to Dressler syndrome alone that justify routine use in the first episode; the autoinflammatory circuit becomes more relevant in recurrences. Biological therapy requires documented activity and a specialist pathway.
Individual predisposition is not defined by a clinically available genetic or immunological test. Previous pericardial episodes, autoimmune diseases, and greater injury may modify risk, but associations derive from limited data and do not permit targeted preventive surveillance; predisposing factors remain largely clinical. Extensive autoimmune testing is not indicated in every typical, self-limited case.

Increased vascular permeability produces protein- and fibrin-rich fluid. If accumulation is slow, the pericardium stretches and tolerates relatively large volumes; if it increases rapidly, even a smaller amount may restrict cardiac filling; the rate of accumulation determines the risk of tamponade. Measurement in millimeters must be interpreted together with hemodynamic signs.
Inflammation produces pain through the parietal pericardium and pleura, fever through systemic mediators, and increased CRP through the hepatic response; these mechanisms are shared with infections and other pericarditides, so the post-infarction context does not confer absolute specificity; the inflammatory profile supports but does not prove Dressler syndrome. Cultures and further tests depend on fever, immune status, and epidemiological risk.

The syndrome is not caused by persistent coronary occlusion, although a late-reperfused infarction may provide more antigen. A new ischemic event may nevertheless reactivate injury and confound the presentation, creating a complex relationship between coronary recurrence and serosal inflammation; the delayed immune mechanism does not replace coronary diagnosis. When troponin and ECG change, the possibility of new necrosis must be addressed independently.

Pathological anatomy, classification, and evolution

The pericardium may show hyperemia, serofibrinous exudate, and fibrin deposition over more extensive surfaces than in localized epistenocardiac pericarditis. The pleurae may also be inflamed and contain fluid, often bilaterally but with possible asymmetry; the serosal distribution explains the clinical variety. Pathological anatomy is rarely necessary for routine diagnosis.
Dressler syndrome is a subtype of post-cardiac injury syndrome, which also includes postpericardiotomy pericarditis and pericarditis after trauma or procedures. In this case, the index event is infarction, while the mechanism and treatment share principles with the other phenotypes; the etiological classification identifies the initial injury. Not every effusion after a procedure or infarction is inflammatory.

The classic latency is two to six weeks, but contemporary descriptions permit a more variable interval, even lasting months. A rigid limit would produce false negatives and false positives, so timing must be combined with a symptom-free phase and new inflammatory reactivation; the latency period nevertheless remains distinctive. Onset within the first few days points toward different mechanisms.
The form may be predominantly pericarditic, pleuritic, or mixed. Pericardial effusion ranges from absent to large; pleural effusion may dominate symptoms and require differentiation from heart failure or infection; a pleural phenotype does not exclude Dressler syndrome. Elevated CRP helps distinguish an active process from a passive collection.

The first episode generally responds within days or weeks, but treatment tapered too rapidly before remission may be followed by a flare. Incessant pericarditis denotes persistence without a symptom-free interval, whereas a recurrence follows an asymptomatic period; the temporal trajectory guides treatment intensity and duration. Terminology must be used consistently during follow-up.
During resolution, CRP normalizes, pain and fever disappear, and effusions diminish. Pericardial enhancement on MRI may persist longer than symptoms and does not automatically require treatment in the absence of significant clinical activity; clinical remission integrates symptoms, biomarkers, and imaging. A single radiological finding must not guide months of treatment without context.

Repeated inflammation may produce thickening, adhesions, and, rarely, constriction. The risk is much lower in idiopathic or post-injury forms than in tuberculous and purulent pericarditis, but persistent congestion requires evaluation; pericardial fibrosis is a rare outcome. Calcification is not expected after a single promptly resolved episode.
The underlying infarction independently evolves into a scar and possible remodeling. Heart failure, aneurysm, and ventricular thrombus may produce effusions or symptoms that overlap with the syndrome, complicating follow-up; the dual pericardial and myocardial course must be monitored separately. Improvement of pericarditis does not demonstrate recovery of ventricular function.

Pleural and pericardial effusions may resolve at different rates. Pain may cease before complete reabsorption, while small residual collections do not imply persistent activity if CRP and clinical findings are normal; conversely, a stable collection with pericardial enhancement may still require specialist interpretation. Discordance between compartments is possible. Follow-up must avoid both treating an isolated image and underestimating new progression.

Signs and symptoms

Pain is generally sharp, worsens with inspiration, coughing, and recumbency, and improves when sitting forward. It may radiate to the shoulder or trapezius and differ from the pressure of the initial infarction, but no description alone eliminates new ischemia; positional pain is a useful clue. ECG and urgent assessment remain necessary if the symptom is severe or new.
Fever, asthenia, myalgia, and reduced appetite provide a more evident systemic dimension than in early pericarditis. High fever, chills, or toxicity nevertheless require a careful search for infection, especially after hospitalization and invasive procedures; late fever is not synonymous with Dressler syndrome. Blood cultures are obtained when the probability of infection justifies them.

A pericardial friction rub may be intermittent and disappear when the effusion separates the layers. A pleural friction rub follows the respiratory cycle and may be located laterally, while crackles and edema also point toward heart failure; auscultatory findings must be reassessed over time. Their absence does not exclude an effusive phenotype.
Dyspnea may result from pain, pleural effusion, pericardial effusion, or post-infarction ventricular dysfunction. Orthopnea, weight gain, and jugular venous congestion point toward heart failure, whereas tachypnea and lateral pain may suggest pleuritis or embolism; multifactorial dyspnea requires cardiac and chest imaging. Attributing it to the syndrome alone may delay heart failure treatment.

A large effusion may cause chest pressure, early satiety, and reduced exercise capacity. Tamponade produces tachycardia, hypotension, pulsus paradoxus, and jugular venous distention, but classic signs vary and ventricular dysfunction may confound them; hemodynamic compromise is an emergency. A stable patient may deteriorate if fluid continues to accumulate.
Pleural effusion may cause lateral pain, dry cough, and dullness to percussion. If unilateral, febrile, or persistent, it must be distinguished from pneumonia, embolism, cancer, and postprocedural collections; pleural involvement broadens the differential diagnosis. Thoracentesis is reserved for diagnostic or therapeutic indications and is not performed automatically to confirm Dressler syndrome.

Palpitations may reflect atrial fibrillation, ectopy, or anxiety; syncope and instability are not ordinary manifestations of uncomplicated disease; these events require monitoring and assessment for arrhythmias, ischemia, or tamponade; arrhythmic symptoms often arise from the infarcted myocardium. Pericarditis may coexist but must not become a universal explanation.
The patient may already have resumed activity and interpret recurrent symptoms as failure of infarction treatment or a new life-threatening event. Clear communication reduces fear, but reassurance is provided only after an adequate assessment; the psychological burden affects quality of life and adherence. Rehabilitation and support should continue during treatment.

Some patients present only with fatigue, low-grade fever, and reduced exercise capacity, without classic pain. In these cases, diagnosis is more difficult and must rest on CRP, effusions, and the absence of alternative explanations because deconditioning and heart failure are common after infarction; a paucisymptomatic phenotype does not permit less rigorous criteria. A response to an anti-inflammatory agent may support but does not retrospectively prove the etiology.

Investigations and diagnosis

Diagnosis requires a recent cardiac injury and a combination of inflammatory manifestations: fever without an alternative cause, pericardial or pleuritic pain, a friction rub, pericardial effusion, and pleural effusion associated with elevated CRP. Traditionally, at least two features are required; the post-injury criteria are broader than the criteria for pericarditis alone. The presence of inflammation distinguishes common mechanical effusions from an active syndrome.
The history reconstructs the date and territory of the infarction, revascularization, any perforation, previous effusions, symptom-free interval, medications, and systemic symptoms. Without this timeline, a residual effusion may be mistaken for new disease; the sequence of events supports causality. A previous echocardiogram is often the most useful comparison.

The ECG may show diffuse ST-segment elevation and PR-segment depression, but scar, aneurysm, conduction blocks, and ischemia alter the tracing. T-wave inversions may belong to infarct evolution and are not specific; serial interpretation distinguishes new abnormalities from preexisting ones. A territorial pattern with ischemic symptoms may require coronary angiography.
CRP documents activity and is followed until remission; ESR, leukocytes, renal function, transaminases, and complete blood count complete assessment and treatment safety. Troponin may remain elevated or increase because of new ischemia and does not confirm Dressler syndrome; the laboratory profile guides diagnosis and treatment. Procalcitonin or cultures are selected if infection is suspected, not routinely.

Echocardiography measures the effusion, its distribution, and its impact, evaluates biventricular function, and looks for other complications. The absence of fluid does not exclude a dry form, whereas an enlarging effusion requires exclusion of bleeding, rupture, or heart failure; the echocardiographic assessment primarily establishes hemodynamic safety. Serial examinations are indicated when the collection is significant or the presentation changes.

Features supporting a diagnosis of Dressler syndrome

• Index injury: documented myocardial infarction followed by a plausible latency interval.
• Serosal manifestations: pericardial or pleuritic pain, a friction rub, or a pericardial or pleural effusion.
• Systemic inflammation: fever without another cause and elevated C-reactive protein.
• Combined criteria: at least two consistent manifestations, not the presence of fluid alone.
• Alternatives excluded: reinfarction, infection, pulmonary embolism, heart failure, and mechanical complications assessed.

Chest radiography and lung ultrasonography identify effusions, consolidation, and edema. Contrast-enhanced CT is useful if embolism or infection remains likely, while cardiac CT describes thickening and loculated collections in selected cases. Chest imaging separates pleuritis from congestion. Radiation and iodine require a question capable of changing management.
Cardiac MRI shows pericardial enhancement and edema and characterizes scar, function, and alternative myocardial diagnoses. It is particularly useful in equivocal, persistent, or recurrent forms and to guide duration in complex cases, but it is not necessary in every typical presentation; pericardial MRI documents tissue activity. A positive finding must be correlated with symptoms and biomarkers.

If fluid is drained because of tamponade, a large symptomatic collection, or etiological uncertainty, analysis includes cell counts, protein, cultures, cytology, and targeted tests. Purely diagnostic drainage of a small effusion is not justified; selective pericardiocentesis addresses a specific indication. Safety depends on echocardiographic guidance, location, and antithrombotic therapy.
Pulmonary embolism deserves attention because recent hospitalization, immobility, and heart failure increase risk, and pleuritic pain, tachycardia, low-grade fever, and an effusion may mimic Dressler syndrome. Clinical probability and imaging are used contextually because D-dimer is often elevated after infarction; a thromboembolic diagnosis must not be excluded by the presence of elevated CRP. A perfusion defect requires completely different treatment.

Infection is assessed particularly rigorously in patients with devices, after vascular or cardiac surgical procedures, and in immunocompromised patients. Endocarditis, catheter infection, and pneumonia may produce fever, effusions, and elevated markers, whereas corticosteroids would worsen their course; infectious disease safety precedes immunosuppression. Echocardiography, cultures, and imaging are selected on the basis of findings, avoiding both omissions and indiscriminate panels.

Treatment and prognosis

In the first symptomatic episode after infarction, high-dose aspirin is preferred, generally 500–1000 mg every six to eight hours or 750–1000 mg three times daily, with gradual tapering after remission. The dose is adjusted for age, bleeding, renal function, and tolerance. High-dose aspirin remains compatible with the antiplatelet indication. The minimum coronary dose is resumed after the anti-inflammatory phase.
Colchicine may be added to reduce persistence and recurrence, typically 0.5 mg once daily below 70 kg or in conditions requiring dose reduction and twice daily in other appropriate adults. In the post-infarction setting, the ACS guideline proposes approximately three months; colchicine without a loading dose improves tolerability. Renal function, hepatic function, and interactions must be reassessed.

A proton pump inhibitor is generally combined with high-dose aspirin, especially with dual antiplatelet therapy or other risk factors. Complete blood count, creatinine, transaminases, and signs of bleeding are monitored for safety; gastroprotection does not eliminate systemic bleeding risk. Alcohol, self-medication with NSAIDs, and herbal products must be discussed.
NSAIDs other than aspirin are avoided when possible during the post-infarction phase because of cardiovascular risk and possible effects on healing. Low- or moderate-dose glucocorticoids, combined with colchicine, are reserved for contraindications, specific etiologies, or failure to respond, with very slow tapering; corticosteroid therapy is not first-line treatment. Rapid tapering below the critical threshold promotes recurrence.

In incessant or recurrent phenotypes that are glucocorticoid-dependent and colchicine-resistant with documented activity, anakinra or rilonacept may be considered according to guidelines and availability. Screening for latent infections, vaccinations, and monitoring are necessary; interleukin-1 blockade derives from robust evidence in the broader recurrent pericarditis population. It is not automatic treatment for a first episode of Dressler syndrome.
Relative rest and avoidance of intense exercise continue until remission of pain, fever, and inflammation. Resumption occurs within the post-infarction rehabilitation program, considering ventricular function, residual ischemia, and arrhythmias in addition to the pericardium; return to exercise is individualized. Prolonged immobility without a reason promotes deconditioning and fear.

An effusion without tamponade is monitored; drainage is indicated for hemodynamic compromise, a large symptomatic collection, or a diagnostic need. Anticoagulants and antiplatelet agents are reassessed if fluid increases or appears hemorrhagic, balancing stent and embolic risks; effusion management depends on the cause and rate of accumulation. Anti-inflammatory therapy does not replace drainage in tamponade.
Most patients respond and have a favorable prognosis, but the overall outcome depends on the infarction, ventricular function, and comorbidities. Clinical, laboratory, and echocardiographic follow-up confirms remission and guides tapering; the integrated prognosis cannot be inferred from pericarditis alone. Secondary prevention and rehabilitation remain essential throughout the care pathway.

Aspirin tapering begins after stable control of pain and inflammation and proceeds in steps, avoiding the simultaneous discontinuation of multiple drugs if the course has been difficult. Colchicine is maintained for the established period and generally does not require gradual tapering, except for individual needs; the tapering sequence permits recognition of reactivation. Any recurrence during tapering should be documented before doses are increased again.

Complications

Recurrence is the most common complication and presents with new pain and increased CRP after a symptom-free interval. Premature treatment tapering and glucocorticoids used early or tapered rapidly may promote it; recurrent pericarditis requires objective confirmation. Not every residual pain represents new inflammation, and MRI may help in equivocal cases.
An effusion may enlarge and produce tamponade, a rare but urgent event. Hypotension, tachycardia, dyspnea, jugular venous distention, and pulsus paradoxus require immediate echocardiography; the cause must include hemopericardium and not only inflammation; late tamponade requires drainage and etiological investigation. Stabilization does not complete management if fluid continues to form.

Persistent pleural effusions cause dyspnea and may become infected or reflect an alternative diagnosis. A large collection may require thoracentesis, whereas small effusions improve with control of inflammation; pleural persistence calls for reassessment of heart failure, embolism, and infection. The side of the effusion alone does not identify the cause.
Constriction is rare but possible after prolonged or recurrent inflammation. Edema, ascites, jugular venous distention, a pericardial knock, and marked ventricular interdependence point toward constrictive physiology and require multimodality imaging; constrictive pericarditis is not diagnosed from thickening alone. Some transient inflammatory forms may regress with treatment.

Gastrointestinal or intracranial bleeding may complicate high-dose aspirin, dual antiplatelet therapy, and anticoagulation. Renal failure increases both drug accumulation and bleeding risk, while colchicine may cause diarrhea, cytopenias, or myopathy in the presence of interactions; treatment toxicity requires active surveillance. The prescription is simplified as soon as marginal benefit diminishes.
Prolonged glucocorticoid therapy may cause diabetes, infections, osteoporosis, myopathy, and treatment dependence. Anti-IL-1 drugs increase the risk of infection and local reactions and require a discontinuation plan because abrupt withdrawal may be followed by recurrence; immunomodulatory complications weigh in the decision. Treatment must reduce overall harm without replacing inflammation with iatrogenic toxicity of equal importance.

A misattribution may be more dangerous than the syndrome: reinfarction treated as pericarditis, embolism mistaken for pleuritis, or endocarditis masked as an immune response. Every atypical presentation, high fever, or instability reopens the entire diagnostic pathway; a missed alternative diagnosis is a preventable complication. A previous diagnosis must not create cognitive anchoring.
Finally, recurrences and fear may interrupt rehabilitation, work, and social activity. Structured follow-up with measurable objectives, instructions about symptom recurrence, and coordination between the cardiologist and primary care physician reduces inappropriate visits and delays; persistent disability deserves the same attention as effusions. Recovery includes a safe return to life in addition to normalization of CRP.

Fragmented care may improperly prolong corticosteroid treatment or duplicate anti-inflammatory drugs if it is unclear which specialist manages tapering. The discharge letter must state the dose, duration, threshold for changes, monitoring, and drugs to avoid, in addition to coronary antithrombotic therapy; treatment responsibility must be explicitly assigned; this simple step reduces toxicity, abrupt discontinuation, and uncoordinated use of the emergency department.
In complex cases, failure of CRP to normalize must not be interpreted without excluding obesity, infection, autoimmune disease, or persistent inflammation from the infarction. Similarly, a normal CRP during treatment does not guarantee that all pain has resolved or is of pericardial origin; biomarker discordance requires clinical judgment. Decisions about intensification with biological drugs or pericardiectomy cannot be based on a single laboratory value.